Formulation and Process Development Strategies for Manufacturing Biopharmaceuticals 2010
DOI: 10.1002/9780470595886.ch27
|View full text |Cite
|
Sign up to set email alerts
|

Strategies for Bulk Storage and Shipment of Proteins

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
8
0

Year Published

2011
2011
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(8 citation statements)
references
References 29 publications
0
8
0
Order By: Relevance
“…However, the previous authors focused on a horizontal freezing geometry that would not prevent the cryoconcentration heterogeneity discussed above. Jameel et al, in their review of bulk storage and shipment strategies, have discussed unidirectional freezing from the perspective of achieving a linearly scalable system and also for reducing cryoconcentration by promoting the formation of dendrites. However, they do not report on the ability to suppress density gradient driven convective flow as our work demonstrates.…”
Section: Introductionmentioning
confidence: 99%
“…However, the previous authors focused on a horizontal freezing geometry that would not prevent the cryoconcentration heterogeneity discussed above. Jameel et al, in their review of bulk storage and shipment strategies, have discussed unidirectional freezing from the perspective of achieving a linearly scalable system and also for reducing cryoconcentration by promoting the formation of dendrites. However, they do not report on the ability to suppress density gradient driven convective flow as our work demonstrates.…”
Section: Introductionmentioning
confidence: 99%
“…Frozen storage increases protein solution stability, extends the drug product shelf life, offers flexibility during manufacturing, mitigates the risk of microbial growth, and eliminates agitation and foaming during transportation (1)(2)(3). Thus, freezing and subsequent thawing (F/T) are integral steps in the manufacturing of most biopharmaceutical products (4).…”
Section: Introductionmentioning
confidence: 99%
“…It is important to ensure that the protein retains its biological activity and native state throughout manufacturing, distribution, and shelf life of the drug product. In this sense, non-native protein aggregates in the drug substance storage phase should be well controlled, as even small levels of aggregates can serve as nuclei for the formation of visible and subvisible particles when the solution is further exposed to fill and finish processing stresses (4).…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations